Stocks and Investing
Stocks and Investing
Tue, August 16, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Higgins Maintained (VRDN) at Strong Buy with Increased Target to $40 on, Aug 16th, 2022
Michael Higgins of Ladenburg Thalmann, Maintained "Viridian Therapeutics, Inc." (VRDN) at Strong Buy with Increased Target from $33 to $40 on, Aug 16th, 2022.
Michael has made no other calls on VRDN in the last 4 months.
There are 2 other peers that have a rating on VRDN. Out of the 2 peers that are also analyzing VRDN, 0 agree with Michael's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Michael
- Mike Kratky of "SVB Leerink" Maintained at Buy with Increased Target to $40 on, Monday, August 15th, 2022
- Kalpit Patel of "B. Riley Securities" Initiated at Strong Buy and Held Target at $25 on, Thursday, June 23rd, 2022
Contributing Sources